Novanta Schedules Presentation at J.P. Morgan Healthcare Conference on January 14, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 15 2025
0mins
Should l Buy NOVT?
Source: Newsfilter
- Conference Announcement: Novanta Inc. is scheduled to present at the J.P. Morgan 44th Annual Healthcare Conference on January 14, 2026, in San Francisco, featuring CEO Matthijs Glastra and CFO Robert Buckley, which highlights the company's leadership in the medical technology sector.
- Industry Impact: This conference will provide Novanta with a platform to showcase its core technology solutions, further solidifying its competitive advantage among medical and advanced technology equipment manufacturers while attracting potential investor interest.
- Technical Expertise: Novanta combines deep proprietary technology expertise in precision medicine, manufacturing, medical solutions, and robotics, enabling it to engineer core components that deliver extreme precision and performance tailored to complex customer applications.
- Growth Drivers: The company's innovative team is committed to driving technological advancements and customer success, and this conference is expected to enhance its market visibility and promote future business growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NOVT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NOVT
About NOVT
Novanta Inc. is a supplier of core technology solutions, which offer medical and advanced industrial original equipment manufacturers. Its segment includes Automation Enabling Technologies and Medical Solutions. The Automation Enabling Technologies segment designs, manufactures and markets laser beam delivery components, laser beam delivery solutions, CO2 lasers, solid state lasers, ultrafast lasers, optical and inductive encoders, precision motors, integrated stepper motors, servo drives, motion control solutions, intelligent robotic end-of-arm technology solutions, and air bearing spindles to customers worldwide. The Medical Solutions segment designs, manufactures and markets a range of medical grade technologies, including medical insufflators and endoscopic pumps and related disposables, laser beam delivery solutions, video processing and streaming and capture, machine vision technologies, radio frequency identification (RFID) technologies, thermal chart recorders, and others.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- New Shareholder Entry: ACK Asset Management acquired 375,000 shares of Novanta in Q4 2026, amounting to $44.62 million, marking a new investment that enhances its positioning in high-growth markets.
- Asset Allocation Shift: Novanta accounts for 5.6% of ACK's 13F AUM, indicating strategic importance in the industrial and infrastructure sectors, despite not being in the top five holdings.
- Strong Financial Performance: Novanta generated $247.8 million in Q3 revenue, up 1.4% year-over-year, with adjusted EBITDA rising from $57 million to $58.1 million, demonstrating competitiveness in the high-precision components market.
- Future Outlook: The company anticipates full-year 2025 revenue between $975 million and $979 million, with adjusted EBITDA of $222 million to $225 million, showcasing potential growth opportunities despite cash flow pressures from inventory and restructuring expenses.
See More
- New Position Disclosure: On February 13, 2026, ACK Asset Management disclosed a new position by acquiring 375,000 shares of Novanta, valued at approximately $44.62 million, marking a significant investment in the company.
- Asset Allocation Ratio: This acquisition represents 5.6% of ACK's 13F AUM, indicating a strong confidence in Novanta's future growth potential amidst a challenging market environment.
- Company Financial Overview: As of February 12, 2026, Novanta's share price stood at $139.29, reflecting a 5.7% decline over the past year and underperforming the S&P 500 by 18.63 percentage points, suggesting market caution regarding its growth prospects.
- Future Outlook: Novanta projects full-year 2025 revenue between $975 million and $979 million, with adjusted EBITDA expected to be between $222 million and $225 million, indicating potential growth opportunities as demand in medical and industrial sectors recovers.
See More
- Market Size Forecast: According to Precedence Research, the global robotics technology market is projected to reach $108.43 billion by 2026, with an anticipated growth of 283% to $416.26 billion by 2035, highlighting the long-term growth potential of the sector.
- BOTZ ETF Key Holdings: The top two holdings of the BOTZ ETF are Nvidia (10.89%) and Fanuc (9.13%), with Nvidia leveraging its advanced chips to significantly impact the AI sector, thereby enhancing investor confidence in robotics applications.
- ROBO ETF Investment Strategy: The primary holding of the ROBO ETF is Novanta (1.94%) along with Fanuc as its second-largest holding, focusing on broader diversification which reduces reliance on any single company, thus providing better risk management amid market volatility.
- Investor Selection Guide: The BOTZ ETF is suited for investors seeking concentrated exposure to major robotics and AI companies, while the ROBO ETF is better for those looking for broader diversification, reflecting the potential returns of different investment strategies within the robotics industry.
See More

- Active Options Trading: Gossamer Bio Inc (GOSS) recorded an options trading volume of 36,131 contracts today, equivalent to approximately 3.6 million shares, representing 73.1% of its average daily trading volume of 4.9 million shares over the past month, indicating strong market interest in its future performance.
- Put Options Highlighted: Notably, the $2 strike put option expiring on February 20, 2026, saw a significant volume of 12,338 contracts traded today, representing about 1.2 million underlying shares, reflecting investor expectations regarding potential downside risks for GOSS's stock price.
- Novanta Options Activity: Concurrently, Novanta Inc (NOVT) experienced an options trading volume of 3,468 contracts, equivalent to approximately 346,800 shares, which accounts for 72.7% of its average daily trading volume of 476,875 shares over the past month, showcasing ongoing market interest in its stock.
- Call Options Trading: Within NOVT's trading, the $140 strike call option expiring on February 20, 2026, stood out with a trading volume of 1,724 contracts today, representing around 172,400 underlying shares, indicating investor optimism regarding its future price potential.
See More
- Active Options Trading: Novanta Inc recorded an options trading volume of 2,174 contracts today, equivalent to approximately 217,400 shares, which represents 45.5% of its average daily trading volume of 478,265 shares over the past month, indicating heightened market interest in the company's future performance.
- High Strike Options Activity: Among these trades, the $140 strike call option stands out with 1,877 contracts traded today, representing about 187,700 underlying shares, reflecting investor expectations for a potential price increase in the future.
- CloudFlare Options Volume: Concurrently, CloudFlare Inc also saw robust options trading with a total of 8,805 contracts, equivalent to approximately 880,500 shares, accounting for 45.2% of its average daily trading volume of 1.9 million shares over the past month, showcasing strong market interest in its stock.
- High Strike Call Options: The $300 strike call option for CloudFlare recorded a trading volume of 2,551 contracts today, representing around 255,100 shares, indicating investor confidence in the company's growth potential moving forward.
See More
- Stock Price Fluctuation Analysis: NOVT's 52-week low is $98.27, while the high is $154.16, with the last trade at $124.69, indicating significant price volatility over the year, reflecting varying market expectations regarding the company's future performance.
- Market Trend Observation: The current stock price of $124.69 is approximately 81% of the 52-week high, suggesting that investor confidence in NOVT remains, despite market uncertainties that could influence future investment decisions.
- Technical Indicator Assessment: NOVT's stock price has crossed above the 200-day moving average, indicating a potential upward trend in the short term, attracting more investor attention and possibly driving further price increases.
- Investor Sentiment Analysis: Although the current stock price is below the 52-week high, it remains above the low, indicating a cautiously optimistic market sentiment towards NOVT's fundamentals, which may affect future capital inflows.
See More








